#ACR25 Abstr#802 In #SLE pts with CLASI-A ≥8, pooled post-hoc analysis of Phase 2 RCT showed enpatoran, oral small mol […]
Effect of BioDMARDs on Diabetes risk in 6400+ Psoriasis pts IL-23i and IL-17Ai associated w/ -lower risks of diabetes https://pbs.twimg.com/profile_images/1800478984926334976/yyyPLP4A_normal.jpg
Can the blood reflect what’s happening in the joint? In early RA, 11 synovial proteins mirrored serum levels, forming https://pbs.twimg.com/profile_images/1525262133575012354/Lfut18gD_normal.jpg
Avacopan in the real world: we need to be braver If we want to get steroid-sparing benefit in AAV, we
A systematic review by Dr. SRamiro et al evaluated efficacy of b/tsDMARDs on peripheral axSpA Majority on bDMARDs (TNFi https://pbs.twimg.com/profile_images/1027501556868870145/2culK0bN_normal.jpg
Miller et al. Fibrinogen for GCA diagnosis and flare identification. Similar to ESR/CRP in diagnosis. For flares, lower https://pbs.twimg.com/profile_images/1389468430160510976/sooz0Ud3_normal.jpg john+RNV2@john…
Cool study using vasculitis patient-powered reserach network (VPPRN) “SNOT-22” tool captures sinonasal symptoms; associ https://pbs.twimg.com/profile_images/1982460526815764480/EQEuBdmh_normal.jpg john+RNV2@john… Sun, 10/26/2025 – 12:54
Poster evaluating representation in trials of AAV and GCA Results mirror those observed in other fields; need to keep a
ASAS recommends standardised reporting for 20 key outcomes in axSpA trials, 10 for all studies, 10 specific to DMARD tri
Fascinating: tDR-1, a microbial sRNA, appears protective for RA in at risk ACPA+ pts: – tDR-1 higher = less develop
#ACR25 Abstr#776 2-Year SELECT-GCA RCT showed that #GCA patients receiving continuous UPA15 to 2-yr maintained their rem https://pbs.twimg.com/profile_images/1625445768768135171/M24lCgC__normal.jpg john+RNV2@john… Sun,
No seasonal pattern in GCA! We have also looked at this in our data and similarly found no trends It
Rheumatoid arthritis and the ‘big bang’ at the ACR! Janet.Pope@sjh… Sun, 10/26/2025 – 12:15
Real-world T2T strategy from MONITOR-PsA cohort: 🎯 At 48 weeks – 33.6% (49/146) of pts achieved PASDAS ‘moderate’ res https://pbs.twimg.com/profile_images/1027501556868870145/2culK0bN_normal.jpg
#0191 We found that in a large South London RA cohort, use of advanced therapy in moderate disease (DAS28 3.2-5.1)
#0776 In the 2-yr SELECT-GCA trial, continued upadacitinib 15mg maintained remission in 69% vs 29% who switched to PBO, https://pbs.twimg.com/profile_images/1489576716322447363/HmrVJtAH_normal.jpg
SELECT-GCA (upadacitinib in GCA for 52w) we hoped it might have ongoing effect post-cessation Do we need to continue up
Albach et al. CAR T-cells in D2T RA. 6 patients. Safety looks ok. ACR20 in 4/6, ACR50 in 2/6. ACPA
Singla et al. In secukinumab phase 3 trials, fungal (inc candida) infections uncommon. 5.51 for sec vs 3.39 for PBO
RheumNow’s expanded coverage of the #ACR2025 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. A https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john…
Not all inflammatory nasal lesions are vasculitis! Dr. Zacharek presents from the ENT perspective @RheumNow #ACR25 http https://pbs.twimg.com/profile_images/1684945388665442304/yPWpfGoX_normal.jpg john+RNV2@john… Sun,
Schmidt et al. 2 year results of SELECT-GCA, upadacitinib in GCA. Remission 69% if upa continued vs 29% if stopped.
AI-enhanced MRI integrating STIR and T1-weighted MRI with BME data reflecting both inflammatory and structural changes, https://pbs.twimg.com/profile_images/926606033270665216/Z42VohYE_normal.jpg john+RNV2@john… Sun, 10/26/2025
SLE Conference Preview: progress in biologics y.yusof@leeds.ac.uk Sun, 10/26/2025 – 14:00
Plenary session at #ACR25! #0772 When should we biopsy in SLE? In pts with uPCR 0.25-0.49 g/g + LN predictors,
Join us at 5pm CST for Day 1 #ACR25 recap! https://t.co/EwZSiPhysF https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Sun, 10/26/2025 – 11:03 RheumNow Dr. John
Early, low level proteinuria is a harbinger in SLE. ~50% with elevated UPCR but <0.5 had actionable LN on early
